FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

washington, D.C. 20549	
------------------------	--

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average	burden								
haa ========	. 0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Nash Huw M.  (Last) (First) (Middle)  C/O STOKE THERAPEUTICS, INC.  45 WIGGINS AVENUE  (Street)						2. Issuer Name and Ticker or Trading Symbol Stoke Therapeutics, Inc. [STOK]  3. Date of Earliest Transaction (Month/Day/Year) 09/01/2020  4. If Amendment, Date of Original Filed (Month/Day/Year)								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner  X Officer (give title Other (specify below)  COO & CBO  6. Individual or Joint/Group Filing (Check Applicable Line)							
BEDFOR	RD M	MA 01730														X Form filed by One Reporting Person  Form filed by More than One Reporting Person					
(City)	(St	tate)	(Zip)													. 5.55					
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
		2. Transact Date (Month/Day	Year) Execu		a. Deemed ecution Date, any onth/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and			nd 5) Securit Benefic Owned		es ially Following	Forn (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership				
									Code	v	Amount	(A) or (D)	Price			ted action(s) 3 and 4)			(Instr. 4)		
Common Stock 09/01/202					020	)		М		5,700	Α	\$2.	\$2.19		5,700		D				
Common Stock 09/01/202					020	20		S <sup>(1)</sup>		5,000	D	\$27.6	\$27.603(2)		700		D				
Common Stock 09/01/202				020	20		S <sup>(1)</sup>		700	D	\$28.7	\$28.7109(3)		0		D					
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	eemed tion Date, h/Day/Year)	4. Transa Code ( 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		vative urities uired or losed 0) rr. 3, 4	Expira	e Exercation D		7. Title and Amount of Securities Underlying Derivative Securit (Instr. 3 and 4)		De Se (In	Price of erivative ecurity estr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	e s illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exerc	isable	Expiration Date	Title	Amou or Numb of Share	ber							
Employee Stock Option (Right to	\$2.19	09/01/2020			M			5,700	(	4)	12/12/2018	Commo	5,70	00	\$0.00	209,530	0	D			

## **Explanation of Responses:**

- 1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- 2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$27.50 to \$27.84 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within
- 3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$28.53 to \$29.06 per share, inclusive. The reporting person undertakes to 2. The reported piece in Commit 7 is a weighted average price. These snares were sold in multiple transactions at prices ranging from \$28.53 to \$29.06 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 4. The option vests 1/48th of the shares monthly, commencing one month from the date of grant, subject to reporting person's continued service through each vesting date.

## Remarks:

/s/ Stephen Tulipano, Attorney- 09/03/2024 in-Fact

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.